DOM In the News
Read about how the Department of Medicine is responding to the outbreak of the coronavirus respiratory illness COVID-19. See related COVID-19 publications.
ZSFG Medicine Grand Rounds - MGR 23028
Associate Professor, Harvard Medical School, Boston, MA
Associate Director, Smith Center for Outcomes Research, Beth Israel Deaconess Medical Center, Boston, MA
Disclosure: Presenter Dhruv S. Kazi, MD, MSc, MS has no financial relationships to disclose. Planners Jessie Holtzman, MD; Elizabeth Harleman, MD; Melody Davenport-McLaughlin, BA, and Evelina Azarian, BA have stated they have no financial relationships to disclose.
Learning Objectives:
- To recognize that the issue of exorbitant drug prices in the US is relatively new, multi-dimensional, and solvable.
- To enumerate the many ways in which the Inflation Reduction Act of 2022 will affect healthcare and health in the US, and to acknowledge the many issues it leaves unsolved.
- To identify that how a society allocates healthcare resources is as much a philosophical decision as it is an economic one (a la Rawls, Sen, and Piketty).
*Views or opinions expressed in MGR are those of the speakers and do not necessarily represent the views or opinions of the organizers or the UCSF DOM.
Accreditation: The University of California, San Francisco School of Medicine (UCSF) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation: UCSF designates this live activity for a maximum of 64 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The above credit is inclusive of all Fiscal year 2022/2023 SFGH Medicine Grand rounds sessions.
Zoom Information
http://tiny.ucsf.edu/DOMGrandRounds
Meeting ID: 968 1679 7792
Password: 1001
Call-in: +1 669 900 6833, +1 213 338 8477, +1 669 219 259
To claim credit for today’s Medicine Grand Rounds:
- Scan the code using your mobile device.
- Follow the link to ww2.highmarksce.com
- Enter your name and email. Select the number of credits claimed and tap Submit
- The link is active from 15 minutes after the close of the session and is open for 30 days.
This presentation will be recorded and is accessible through My Access
https://lecture.ucsf.edu/ets/Catalog/Full/ab21c2921423425398199ec7e0720d6a2
CMS Requests Public Comment on NCA Tracking Sheet
The Food and Drug Administration (FDA) recently approved, aducanumab (brand name Aduhelm™) for the treatment of Alzheimer’s disease with relabelling for use only in mild Alzheimer's Disease. There is a great deal of controversy about this approval and CMS is calling for public comment on whether or how it should cover the expenses for this medication and have opened a 30 day period for public comment. AGS opposed the approval of aducanumab and arguments for and against its approval and the options for Centers for Medicare & Medicaid Services (CMS) were recently discussed in this weeks JAMA Internal Medicine. Please make your opinions known "National Coverage Analysis (NCA) Tracking Sheet for Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease". Please submit comments by August 11, 2021.